← Leaderboards
Remi Adelaiye-Ogala
State University Of New York At Buffalo
$2,864,216
Attributed
$2,864,216
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,864,216 · 2
By mechanism
R37$1,633,514 · 1
R01$1,230,702 · 1
Top collaborators
No co-investigators on record.
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Martin Kaczocha$9,793,941
Others in their field
Other Rising Stars on “Resolution”
- Gene Garrard Olinger · University Of Texas Med Br Galveston$23,000,000
- Michelle Rives · Baylor College Of Medicine$20,650,593
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,500,724
- Daofeng Li · Salk Institute For Biological Studies$9,887,266
- James Cappo · National Jewish Health$9,298,220
- Peter N. Schmidt · Rho Federal Systems Division, Inc.$8,977,742
Research focus
ResolutionResistanceMalignant Neoplasm Of ProstatePatient Derived Xenograft ModelPlayReceptor ExpressionEnzalutamideInterestMultiple OmicsMediatingPharmacologicPhysiciansAntagonistProteomicsCellsChromatinExposure ToBindingAdvanced DiseaseChip-SeqAndrogen ReceptorCancer CellAdvanced Prostate CancerScientist
Grant awards (5)
Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancer$588,399
R01 · FY2025 · CA · contact PI
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers$541,248
R37 · FY2025 · CA · contact PI
Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancer$642,303
R01 · FY2024 · CA · contact PI
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers$503,083
R37 · FY2024 · CA · contact PI
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers$589,183
R37 · FY2023 · CA · contact PI